Reteena develops human-friendly solutions focused on accessible Alzheimer's diagnosis and therapy support. The company creates specialized tools, including an LLM-based memory assistant for reminiscence therapy and deep learning frameworks for low-field MRI segmentation. Their product suite leverages AI and genomics to improve early AD detection and patient care pathways.
Funding
Funding not disclosed
Founders
Product
Problem
Low-field MRI scans often suffer from poor resolution, hindering the early and accurate detection of subtle brain changes indicative of prodromal Alzheimer's disease. Traditional methods for enhancing MRI resolution can be expensive and inaccessible, limiting their widespread use in early diagnosis.
Solution
Reteena is developing an open-source, AI-based framework designed to enhance the resolution of low-field MRI scans. This framework aims to improve the clarity of brain images, facilitating earlier and more accurate detection of prodromal Alzheimer's disease. By providing a cost-effective and accessible solution, Reteena seeks to reduce healthcare diagnosis costs and improve accessibility for patients who may not have access to high-field MRI technology. The framework leverages deep learning techniques to reconstruct high-resolution images from low-resolution inputs.
Target Audience
The primary target audience includes healthcare providers, radiologists, and researchers focused on early Alzheimer's disease detection, particularly those in resource-constrained settings or with limited access to high-field MRI technology.
Features
- AI-powered image resolution enhancement for low-field MRI scans
- Open-source framework promoting transparency and continuous improvement
- Deep learning models for image reconstruction
- Digital twin platform for Alzheimer's patients, featuring a chatbot-style interaction for memory storage and recall